Ładuje się......
The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model
Background: Children with cystic fibrosis (CF) are at higher risk of severe respiratory syncytial virus (RSV) infection, which can lead to a decline in lung function. A monoclonal antibody, palivizumab (PMB), effectively prevents RSV hospitalizations; however, the high cost of PMB, approximately C$1...
Zapisane w:
| Wydane w: | Hum Vaccin Immunother |
|---|---|
| Główni autorzy: | , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Taylor & Francis
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5360124/ https://ncbi.nlm.nih.gov/pubmed/27768505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1235670 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|